
2020 Annual report
2020 marks the 10th anniversary of our first call for projects! Learn about our researchers, their scientific advances and how some of their discoveries have been translated into applications for human health.
2020 marks the 10th anniversary of our first call for projects! Learn about our researchers, their scientific advances and how some of their discoveries have been translated into applications for human health.
François Fuks and his team demonstrated the role of the regulation of RNA epigenetics by the FTO enzyme in the development of cancer metastasis.
From disruptive research of scientific founder Benoit Vanhollebeke to the development of blood-brain barrier pharmaceuticals aiming at repairing neurovascular function and neurodegenerative diseases.
Patrice Cani et his team discovered the properties displayed by D. welbionis, a new bacterium present in 70% of the population, that open the doors for potential treatment for type 2 diabetes, obesity and inflammatory diseases.
Pierre Close and Francesca Rapino unfolded how the regulation of transfer RNAs and modification of their anticodon impacted the dynamics of protein synthesis and regulated protein folding and stability.
Decio Eizirik et son équipe décrivent des signatures moléculaires similaires entre différentes maladies auto-immunes, identifiant des voies clés qui pourraient être ciblées pour la thérapie.
Cédric Blanpain and his team identified the functions of FAT1, one of the most frequently mutated cancer gene drivers, uncovering that FAT1 mutations promote invasive features, metastasis and resistance to commonly used anti-cancer drugs
Cédric Blanpain is awarded the Francqui-Collen Prize for his fundamental research in cancer and stem cells biology.
Kaneka and its Walloon subsidiary, Kaneka Eurogentec S.A., enter into a partnership with Jean-François Collet's laboratory by funding a new joint research group at the Duve Institute.
WELBIO lance aujourd’hui une plateforme digitale permettant aux citoyens de se déclarer volontaires pour des études cliniques relatives au Covid-19 : https://rechercheclinique.be/
These results from the team of Jean-Luc Balligand pave the way for the development of more potent molecules to block aquaporin and treat heart failure more efficiently.
This jammer prevents proper regulation of sugar, causing insulin resistance in people with diabetes. Patrice Cani and colleagues also discovered that a lipid produced by our body helps preventing this dysfunction.